Daiichi Sankyo Company, Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
DSNKY Over the counter 2830 www.daiichisankyo.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Daiichi Sankyo Company, Limited

Asian Market Opportunities: Shanghai Aohua Photoelectricity Endoscope And 2 More Stocks That May Be Trading At A Discount - Nov 10th, 2025 9:38 pm
Asian Stocks Estimated To Be Up To 38.1% Below Intrinsic Value - Nov 10th, 2025 3:40 pm
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo - Nov 10th, 2025 5:00 am
3 Global Stocks That May Be Undervalued In November 2025 - Nov 10th, 2025 2:38 am
Asian Value Stocks Priced Below Estimated Worth In November 2025 - Nov 9th, 2025 9:37 pm
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 37.6% - Nov 9th, 2025 3:34 pm
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 46.1% - Nov 5th, 2025 9:37 pm
3 Asian Stocks That Might Be Trading Below Estimated Value In November 2025 - Nov 5th, 2025 3:34 pm
Asian Market: 3 Stocks That May Be Trading Below Their Estimated Value - Nov 4th, 2025 9:37 pm
Asian Value Stocks Trading At Estimated Discounts In November 2025 - Nov 4th, 2025 3:34 pm
Gastric Cancer Global and Regional Market Analysis 2025-2035: Focus on Treatment Type and End User with Profiles of Daiichi Sankyo, AstraZeneca, Roche, Merck & Co., Eli Lilly & Company and More - Nov 4th, 2025 9:36 am
Lung Cancer Antibody Drug Conjugates Research 2025: A $2 Billion Opportunity in 2030, Led by AstraZeneca, Daiichi Sankyo, Pfizer, and BMS Advancing Targeted Therapies Against HER2, TROP-2, and B7-H3 - Nov 3rd, 2025 4:06 am
Breast Cancer Antibody Drug Conjugates Market Research 2025-2030: $7 Billion Market Led by Daiichi Sankyo and AstraZeneca, with Rising Competition from Roche, Pfizer/Seagen, ADC Therapeutics - Nov 3rd, 2025 3:54 am
Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives - Nov 1st, 2025 6:15 pm
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer - Oct 30th, 2025 7:00 pm
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results - Oct 30th, 2025 4:30 am
AstraZeneca PLC (AZN): A Bull Case Theory - Oct 22nd, 2025 12:31 pm
AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure - Oct 20th, 2025 1:45 pm
What Recent Oncology Deal Means for Daiichi Sankyo Shares in 2025 - Oct 19th, 2025 4:06 pm
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial - Oct 19th, 2025 7:00 am